Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity

T Robson, Jenny Worthington, Stephanie McKeown, DG Hirst

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Radiotherapy (RT) is a well established modality for treating many forms of cancer. However, despite many improvements in treatment planning and delivery, the total radiation dose is often too low for tumor cure, because of the risk of normal tissue damage. Gene therapy provides a new adjunctive strategy to enhance the effectiveness of RT, offering the potential for preferential killing of cancer cells and sparing of normal tissues. This specificity can be achieved at several levels including restricted vector delivery, transcriptional targeting and specificity of the transgene product. This review will focus on those gene therapy strategies that are currently being evaluated in combination with RT, including the use of radiation sensitive promoters to control the timing and location of gene expression specifically within tumors. Therapeutic transgenes chosen for their radiosensitizing properties will also be reviewed, these include: gene correction therapy, in which normal copies of genes responsible for radiation-induced apoptosis are transfected to compensate for the deletions or mutated variants in tumor cells (p53 is the most widely studied example). enzymes that synergize the radiation effect, by generation of a toxic species from endogenous precursors (e.g., inducible nitric oxide synthase) or by activation of non toxic prodrugs to toxic species (e.g., herpes simplex virus thymidine kinase/ganciclovir) within the target tissue. conditionally replicating oncolytic adenoviruses that synergize the radiation effect. membrane transport proteins (e.g., sodium iodide symporter) to facilitate uptake of cytotoxic radionuclides. The evidence indicates that many of these approaches are successful for augmenting radiation induced tumor cell killing with clinical trials currently underway.
    LanguageEnglish
    Pages343-361
    JournalTechnology in Cancer Research and Treatment
    Volume4
    Issue number4
    Publication statusPublished - Aug 2005

    Fingerprint

    Radiation Tolerance
    Poisons
    Genetic Therapy
    Radiation
    Neoplasms
    Radiotherapy
    Radiation Effects
    Transgenes
    Therapeutics
    Ganciclovir
    Membrane Transport Proteins
    Thymidine Kinase
    Prodrugs
    Nitric Oxide Synthase Type II
    Simplexvirus
    Adenoviridae
    Radioisotopes
    Clinical Trials
    Apoptosis
    Gene Expression

    Cite this

    Robson, T., Worthington, J., McKeown, S., & Hirst, DG. (2005). Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. Technology in Cancer Research and Treatment, 4(4), 343-361.
    Robson, T ; Worthington, Jenny ; McKeown, Stephanie ; Hirst, DG. / Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. In: Technology in Cancer Research and Treatment. 2005 ; Vol. 4, No. 4. pp. 343-361.
    @article{ff599e9558904a72a3e84dd13111a252,
    title = "Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity",
    abstract = "Radiotherapy (RT) is a well established modality for treating many forms of cancer. However, despite many improvements in treatment planning and delivery, the total radiation dose is often too low for tumor cure, because of the risk of normal tissue damage. Gene therapy provides a new adjunctive strategy to enhance the effectiveness of RT, offering the potential for preferential killing of cancer cells and sparing of normal tissues. This specificity can be achieved at several levels including restricted vector delivery, transcriptional targeting and specificity of the transgene product. This review will focus on those gene therapy strategies that are currently being evaluated in combination with RT, including the use of radiation sensitive promoters to control the timing and location of gene expression specifically within tumors. Therapeutic transgenes chosen for their radiosensitizing properties will also be reviewed, these include: gene correction therapy, in which normal copies of genes responsible for radiation-induced apoptosis are transfected to compensate for the deletions or mutated variants in tumor cells (p53 is the most widely studied example). enzymes that synergize the radiation effect, by generation of a toxic species from endogenous precursors (e.g., inducible nitric oxide synthase) or by activation of non toxic prodrugs to toxic species (e.g., herpes simplex virus thymidine kinase/ganciclovir) within the target tissue. conditionally replicating oncolytic adenoviruses that synergize the radiation effect. membrane transport proteins (e.g., sodium iodide symporter) to facilitate uptake of cytotoxic radionuclides. The evidence indicates that many of these approaches are successful for augmenting radiation induced tumor cell killing with clinical trials currently underway.",
    author = "T Robson and Jenny Worthington and Stephanie McKeown and DG Hirst",
    year = "2005",
    month = "8",
    language = "English",
    volume = "4",
    pages = "343--361",
    journal = "Technology in Cancer Research and Treatment",
    issn = "1533-0346",
    number = "4",

    }

    Robson, T, Worthington, J, McKeown, S & Hirst, DG 2005, 'Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity', Technology in Cancer Research and Treatment, vol. 4, no. 4, pp. 343-361.

    Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. / Robson, T; Worthington, Jenny; McKeown, Stephanie; Hirst, DG.

    In: Technology in Cancer Research and Treatment, Vol. 4, No. 4, 08.2005, p. 343-361.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity

    AU - Robson, T

    AU - Worthington, Jenny

    AU - McKeown, Stephanie

    AU - Hirst, DG

    PY - 2005/8

    Y1 - 2005/8

    N2 - Radiotherapy (RT) is a well established modality for treating many forms of cancer. However, despite many improvements in treatment planning and delivery, the total radiation dose is often too low for tumor cure, because of the risk of normal tissue damage. Gene therapy provides a new adjunctive strategy to enhance the effectiveness of RT, offering the potential for preferential killing of cancer cells and sparing of normal tissues. This specificity can be achieved at several levels including restricted vector delivery, transcriptional targeting and specificity of the transgene product. This review will focus on those gene therapy strategies that are currently being evaluated in combination with RT, including the use of radiation sensitive promoters to control the timing and location of gene expression specifically within tumors. Therapeutic transgenes chosen for their radiosensitizing properties will also be reviewed, these include: gene correction therapy, in which normal copies of genes responsible for radiation-induced apoptosis are transfected to compensate for the deletions or mutated variants in tumor cells (p53 is the most widely studied example). enzymes that synergize the radiation effect, by generation of a toxic species from endogenous precursors (e.g., inducible nitric oxide synthase) or by activation of non toxic prodrugs to toxic species (e.g., herpes simplex virus thymidine kinase/ganciclovir) within the target tissue. conditionally replicating oncolytic adenoviruses that synergize the radiation effect. membrane transport proteins (e.g., sodium iodide symporter) to facilitate uptake of cytotoxic radionuclides. The evidence indicates that many of these approaches are successful for augmenting radiation induced tumor cell killing with clinical trials currently underway.

    AB - Radiotherapy (RT) is a well established modality for treating many forms of cancer. However, despite many improvements in treatment planning and delivery, the total radiation dose is often too low for tumor cure, because of the risk of normal tissue damage. Gene therapy provides a new adjunctive strategy to enhance the effectiveness of RT, offering the potential for preferential killing of cancer cells and sparing of normal tissues. This specificity can be achieved at several levels including restricted vector delivery, transcriptional targeting and specificity of the transgene product. This review will focus on those gene therapy strategies that are currently being evaluated in combination with RT, including the use of radiation sensitive promoters to control the timing and location of gene expression specifically within tumors. Therapeutic transgenes chosen for their radiosensitizing properties will also be reviewed, these include: gene correction therapy, in which normal copies of genes responsible for radiation-induced apoptosis are transfected to compensate for the deletions or mutated variants in tumor cells (p53 is the most widely studied example). enzymes that synergize the radiation effect, by generation of a toxic species from endogenous precursors (e.g., inducible nitric oxide synthase) or by activation of non toxic prodrugs to toxic species (e.g., herpes simplex virus thymidine kinase/ganciclovir) within the target tissue. conditionally replicating oncolytic adenoviruses that synergize the radiation effect. membrane transport proteins (e.g., sodium iodide symporter) to facilitate uptake of cytotoxic radionuclides. The evidence indicates that many of these approaches are successful for augmenting radiation induced tumor cell killing with clinical trials currently underway.

    M3 - Article

    VL - 4

    SP - 343

    EP - 361

    JO - Technology in Cancer Research and Treatment

    T2 - Technology in Cancer Research and Treatment

    JF - Technology in Cancer Research and Treatment

    SN - 1533-0346

    IS - 4

    ER -